BRIEF published on 11/19/2024 at 22:35, 1 day 11 hours ago Abivax Launches ATM Program on Nasdaq Common Shares Biotechnology Funding Nasdaq ATM Program
PRESS RELEASE published on 11/19/2024 at 22:30, 1 day 12 hours ago Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax establishes an At-the-Market (ATM) Program on Nasdaq, allowing issuance and sale of ordinary shares to raise up to $150 million. Implementation involves Piper Sandler & Co. as sales agent Ordinary Shares Abivax Nasdaq ATM Program Piper Sandler
BRIEF published on 11/14/2024 at 22:06, 6 days 12 hours ago Abivax Releases Q3 2024 Financial Results Financial Results Biotechnology Abivax Ulcerative Colitis Q3 2024
PRESS RELEASE published on 11/14/2024 at 22:01, 6 days 12 hours ago Abivax presents third quarter 2024 key financial information Abivax presents key financial information for the third quarter of 2024. The company announced updates on operational goals and debt status. Details on Abivax's cash and principal debt outstanding are provided Financial Information Abivax Quarter Results Clinical-stage Biotechnology Debt Status
BRIEF published on 11/13/2024 at 22:06, 7 days 12 hours ago Abivax Appoints Mark Stenhouse as Observer and Strategic Advisor Biotechnology Abivax Obefazimod Appointment Mark Stenhouse
PRESS RELEASE published on 11/13/2024 at 22:01, 7 days 12 hours ago Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax Abivax appoints Mark Stenhouse, former Prometheus COO, as Board Observer & Advisor, bringing extensive biopharma experience to support clinical therapeutics development Abivax Mark Stenhouse Prometheus Board Observer Clinical Therapeutics
BRIEF published on 10/11/2024 at 18:05, 1 month 9 days ago ABIVAX terminates its liquidity contract Liquidity Contract Biotechnology Termination Trading Abivax
BRIEF published on 10/11/2024 at 18:05, 1 month 9 days ago ABIVAX: Number of Shares and Voting Rights as of September 30, 2024 Euronext Paris Share Capital Voting Rights AMF Abivax
PRESS RELEASE published on 10/11/2024 at 18:00, 1 month 9 days ago ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement. Abivax terminates liquidity contract with TSAF SA, releasing details of assets in the account and transactions. Company focuses on developing therapies for chronic inflammatory diseases Liquidity Contract Termination Abivax Therapeutics Immune Response
BRIEF published on 10/07/2024 at 22:06, 1 month 13 days ago Abivax celebrates Nobel Prize for microRNA discovery Abivax Obefazimod Medical Research MicroRNA Nobel Prize
Published on 11/21/2024 at 10:03, 27 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 30 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 30 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 55 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 5 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:04, 25 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 28 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 30 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 30 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 29 minutes ago Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 06:58, 3 hours 32 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 10 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 45 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 45 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
